{"url_path":"/sec/ptpi/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 EXHIBITS.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1815903/0001104659-26-060359-index.html","accession_number":"0001104659-26-060359","cik":"0001815903","ticker":"PTPI","issuer_name":"Petros Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1815903/0001104659-26-060359-index.html","primary_entity_key":"0001815903","primary_entity_name":"Petros Pharmaceuticals, Inc."},"word_count":220,"has_tables":true,"body_markdown":"**ITEM 6. EXHIBITS.**\n\n**Exhibit No.**\n\n  ​ ​ ​\n\n**Description**\n\n31.1*\n\n​\n\n[Rule 13a-14(a)/15d-14(a) Certification – Principal Executive Officer.](tmb-20260331xex31d1.htm)\n\n31.2*\n\n​\n\n[Rule 13a-14(a)/15d-14(a) Certification – Principal Financial Officer.](tmb-20260331xex31d2.htm)\n\n32.1**\n\n​\n\n[Section 1350 Certification – Principal Executive Officer.](tmb-20260331xex32d1.htm)\n\n32.2**\n\n​\n\n[Section 1350 Certification – Principal Financial Officer.](tmb-20260331xex32d2.htm)\n\n101\n\n​\n\nThe following materials from Petros Pharmaceuticals, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) Consolidated Balance Sheets; (ii) Consolidated Statements of Operations; (iii) Consolidated Changes in Stockholders’ Equity/Members’ Capital; (iv) Consolidated Statements of Cash Flows; and (v) Notes to the Condensed Consolidated Financial Statements.\n\n104\n\n​\n\nCover Page Interactive Data File, formatted in iXBRL and contained in Exhibit 101.\n\n*\n\nFiled herewith.\n\n**\n\nFurnished herewith.\n\n​\n\n29\n\n[Table of Contents](#TOC)\n\n​\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n​\n\n​\n\nPetros Pharmaceuticals, Inc.\n\n​\n\n​\n\n​\n\nDate: May 13, 2026\n\nBy:\n\n/s/ Fady Boctor\n\n​\n\n​\n\nFady Boctor\n\n​\n\n​\n\nChief Commercial Officer and Principal Executive Officer\n\n​\n\n​\n\n​\n\nDate: May 13, 2026\n\nBy:\n\n/s/ Mitchell Arnold\n\n​\n\n​\n\nMitchell Arnold\n\n​\n\n​\n\nVice President of Finance and Principal Financial Officer\n\n​\n\n​\n\n​\n\n​\n\n30"}